DDInter1372 DDInter1376
An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Oxymorphone {u} (Compound) resembles {v} (Compound) Dihydrocodeine
Oxymorphone {u} (Compound) resembles {v} (Compound) Methylnaltrexone
Oxymorphone {u} (Compound) binds {v} (Gene) OPRK1
Oxymorphone {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Oxymorphone {u} (Compound) causes {v} (Side Effect) Dyspnoea
Oxymorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propantheline
Oxymorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Oxymorphone {u} may lead to a major life threatening interaction when taken with {v} Alvimopan
Oxymorphone {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Oxymorphone {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxone
Oxymorphone (Compound) resembles Dihydrocodeine (Compound)
Oxymorphone (Compound) resembles Methylnaltrexone (Compound)
Oxymorphone (Compound) binds OPRK1 (Gene)
Oxymorphone (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Oxymorphone (Compound) causes Dyspnoea (Side Effect)
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxymorphone may lead to a major life threatening interaction when taken with Alvimopan
Oxymorphone may lead to a major life threatening interaction when taken with Bupropion
Oxymorphone (Compound) resembles Naloxone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone